Cargando…

Leucine rich repeat kinase 2 (LRRK2) GLY2019SER mutation is absent in a second cohort of Nigerian Africans with Parkinson disease

To date the LRRK2 p.G2019S mutation remains the most common genetic cause of Parkinson disease (PD) worldwide. It accounts for up to 6% of familial and approximately 1.5% of sporadic cases. LRRK2 has a kinase enzymatic domain which provides an attractive potential target for drug therapies and LRRK2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okubadejo, Njideka U., Rizig, Mie, Ojo, Oluwadamilola O., Jonvik, Hallgeir, Oshinaike, Olajumoke, Brown, Emmeline, Houlden, Henry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277104/ https://www.ncbi.nlm.nih.gov/pubmed/30507963 http://dx.doi.org/10.1371/journal.pone.0207984

Ejemplares similares

Clinical profile of parkinsonism and Parkinson's disease in Lagos, Southwestern Nigeria
por: Okubadejo, Njideka U, et al.
Publicado: (2010)

Primary Headache Disorders at a Tertiary Health Facility in Lagos, Nigeria: Prevalence and Consultation Patterns
por: Oshinaike, Olajumoke, et al.
Publicado: (2014)

Comparison of the Minimental State Examination Scale and the International HIV Dementia Scale in Assessing Cognitive Function in Nigerian HIV Patients on Antiretroviral Therapy
por: Oshinaike, O. Olajumoke, et al.
Publicado: (2012)

Influence of Age and Neurotoxic HAART Use on Frequency of HIV Sensory Neuropathy
por: Oshinaike, Olajumoke, et al.
Publicado: (2012)

Analysis of Nigerians with Apparently Sporadic Parkinson Disease for Mutations in LRRK2, PRKN and ATXN3
por: Okubadejo, Njideka, et al.
Publicado: (2008)

Role of LRRK2 variant p.Gly2019Ser in patients with Parkinsonism
por: Sadhukhan, Dipanwita, et al.
Publicado: (2020)

Exploratory study of plasma total homocysteine and its relationship to short-term outcome in acute ischaemic stroke in Nigerians
por: Okubadejo, Njideka U, et al.
Publicado: (2008)

The impact of sex on blood pressure and anthropometry trajectories from early adulthood in a Nigerian population: insights into women’s cardiovascular disease risk across the lifespan
por: Adegoke, Oluseyi, et al.
Publicado: (2022)

MAPT allele and haplotype frequencies in Nigerian Africans: population distribution and association with Parkinson’s disease risk and age at onset
por: Okunoye, Olaitan, et al.
Publicado: (2023)

Frequency of cognitive impairment and depression in Parkinson's disease: A preliminary case-control study
por: Ojo, Oluwadamilola O., et al.
Publicado: (2012)

Prevalence of essential tremor in urban Lagos, Nigeria: a door-to-door community-based study
por: Okubadejo, Njideka U, et al.
Publicado: (2012)

The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study
por: Latourelle, Jeanne C, et al.
Publicado: (2008)

Review of the epidemiology and variability of LRRK2 non-p.Gly2019Ser pathogenic mutations in Parkinson’s disease
por: Turski, Paweł, et al.
Publicado: (2022)

Association of body mass index and abdominal adiposity with atherogenic lipid profile in Nigerians with type 2 diabetes and/or hypertension
por: Fasanmade, Olufemi A., et al.
Publicado: (2013)

Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease
por: Brown, Emmeline E., et al.
Publicado: (2021)

Medication Adherence Among Nigerians with Schizophrenia: Correlation Between Clinico-Demographic Factors and Quality of Life
por: Ogunnubi, Oluseun P., et al.
Publicado: (2017)

Proton Conduction in Gly-X (X = Ser, Ser-Gly-Ser) and GS50
por: Semizo, Hitoki, et al.
Publicado: (2023)

Midbrain organoids mimic early embryonic neurodevelopment and recapitulate LRRK2-p.Gly2019Ser-associated gene expression
por: Zagare, Alise, et al.
Publicado: (2022)

Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease
por: Lee, Byoung Dae, et al.
Publicado: (2010)

LRRK2 Mutations and Asian Disease-Associated Variants in the First Parkinson's Disease Cohort from Kazakhstan
por: Kaiyrzhanov, Rauan, et al.
Publicado: (2020)

LRRK2 Gly2019Ser Mutation Promotes ER Stress via Interacting with THBS1/TGF‐β1 in Parkinson's Disease
por: Yao, Longping, et al.
Publicado: (2023)

Prospective assessment of the risk of obstructive sleep apnea in patients attending a tertiary health facility in Sub-Saharan Africa
por: Ozoh, Obianuju Beatrice, et al.
Publicado: (2014)

Prevalence of hypertension and blood pressure profile amongst urban-dwelling adults in Nigeria: a comparative analysis based on recent guideline recommendations
por: Okubadejo, Njideka U., et al.
Publicado: (2019)

Prevalence of obesity and an interrogation of the correlation between anthropometric indices and blood pressures in urban Lagos, Nigeria
por: Adegoke, Oluseyi, et al.
Publicado: (2021)

APOE E4 is associated with impaired self-declared cognition but not disease risk or age of onset in Nigerians with Parkinson’s disease
por: Okubadejo, Njideka U., et al.
Publicado: (2022)

Telemedicine ready or not? A cross-sectional assessment of telemedicine maturity of federally funded tertiary health institutions in Nigeria
por: Olufunlayo, Tolulope F, et al.
Publicado: (2023)

Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson’s disease and beyond
por: Bae, Jae Ryul, et al.
Publicado: (2015)

Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia
por: Maekawa, Tatsunori, et al.
Publicado: (2016)

The tale of proteolysis targeting chimeras (PROTACs) for Leucine‐Rich Repeat Kinase 2 (LRRK2)
por: Konstantinidou, Markella, et al.
Publicado: (2020)

Determinants of COVID-19 vaccine uptake among Nigerians: evidence from a cross-sectional national survey
por: Ojo, Temitope Olumuyiwa, et al.
Publicado: (2023)

Leucine‐rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes
por: Mercatelli, Daniela, et al.
Publicado: (2019)

Identification and Characterization of a Leucine-Rich Repeat Kinase 2 (LRRK2) Consensus Phosphorylation Motif
por: Pungaliya, Pooja P., et al.
Publicado: (2010)

Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies
por: Davies, Paul, et al.
Publicado: (2013)

Screening for Novel LRRK2 Inhibitors Using a High-Throughput TR-FRET Cellular Assay for LRRK2 Ser935 Phosphorylation
por: Hermanson, Spencer B., et al.
Publicado: (2012)

A leucine‐rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls
por: Vissers, Maurits F. J. M., et al.
Publicado: (2023)

Frequency of complementary and alternative medicine utilization in hypertensive patients attending an urban tertiary care centre in Nigeria
por: Amira, Oluwatoyin C, et al.
Publicado: (2007)

Leucine-rich repeat kinase LRRK1 regulates endosomal trafficking of the EGF receptor
por: Hanafusa, Hiroshi, et al.
Publicado: (2011)

Leucine-Rich Repeat Kinase 2 (Lrrk2)-Sensitive Na(+)/K(+) ATPase Activity in Dendritic Cells
por: Hosseinzadeh, Zohreh, et al.
Publicado: (2017)

Leucine-rich repeat kinase-2 (LRRK2) modulates paraquat-induced inflammatory sickness and stress phenotype
por: Rudyk, Chris, et al.
Publicado: (2019)

Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity
por: Fernández, Belén, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ddh6b567q8li75o766dq5b1ae9